Chronic Pain Clinical Trial
Official title:
Mindfulness Combined With Virtual Exercise Online (MOVE) Compared With a Self-Management Guide for Adults With Chronic Pain: Study Protocol for a Feasibility Randomised Controlled Trial
NCT number | NCT04899622 |
Other study ID # | MOVE-Online |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | July 1, 2022 |
Verified date | October 2022 |
Source | University College Dublin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to assess the feasibility and acceptability of a combined Mindfulness Based Stress Reduction (MBSR) and exercise online programme compared to an online self-management guide. Pain management programmes are the recommended treatment for chronic pain, however a number of barriers to their widespread implementation have been identified including geographical distance from speciality programmes, functional disability limiting the mobility of people with CP and economic limitations(1). eHealth interventions have the potential to address a number of these barriers and recent reviews have reported reductions in pain(2), improved knowledge and understanding about chronic pain and chronic pain management, improved function(3) and improvements in quality of life(4) following eHealth interventions. The intervention in this study will be delivered online. Participants will be randomly allocated to a combined MBSR and exercise programme (Group A) or an online self-management guide (Group B). Group A will take part in an 8 week live online weekly mindfulness sessions based on the Mindfulness Based Stress Reduction (MBSR) programme facilitated by a qualified mindfulness teacher, in addition to a supervised exercise classes led by a Physiotherapist. Group B will receive access to an 8 week online self-management guide containing 8 self-directed guides, which will be made available to participants biweekly. Outcomes of feasibility and acceptability will be investigated in addition to a preliminary examination of between group clinical effects at baseline immediately post intervention and at a three month follow up, using validated patient reported outcome measures. In addition all participants will wear a Fitbit activity monitor for the duration of the eight-week interventions to capture activity measures. A qualitative study will also be conducted to gather participants' perceptions of the programme and its usefulness
Status | Completed |
Enrollment | 96 |
Est. completion date | July 1, 2022 |
Est. primary completion date | March 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: •. Aged >18 years - Diagnosis of chronic pain by a Consultant in Pain Medicine or General Practitioner - Presence of pain NRS = 3 of greater than three months' duration - Ability to provide informed consent - Ability to communicate in English and understand English Exclusion criteria: - Need for further diagnostic evaluation (determined by doctor) - Presence of any contraindications to participation in an exercise programme E.g. severe shortness of breath at rest, angina, uncontrolled diabetes or epilepsy, recent (previous 3 weeks) myocardial infarction, pulmonary embolism, deep vein thrombosis or asthma attack. - Presence of active cancer - Concurrent participation (or in the previous 3 months) with any form of psychological, physiotherapy or supervised exercise in addition to the study intervention. - Presence of substance misuse (diagnosed by the Pain Consultant/GP). - Inability to take part in an online exercise programme - Standard MBSR exclusion criteria |
Country | Name | City | State |
---|---|---|---|
Ireland | University College Dublin | Dublin |
Lead Sponsor | Collaborator |
---|---|
Orla Deegan | Mater Misericordiae University Hospital, University College Dublin |
Ireland,
Bender JL, Radhakrishnan A, Diorio C, Englesakis M, Jadad AR. Can pain be managed through the Internet? A systematic review of randomized controlled trials. Pain. 2011 Aug;152(8):1740-1750. doi: 10.1016/j.pain.2011.02.012. Epub 2011 May 11. Review. — View Citation
Keogh E, Rosser BA, Eccleston C. e-Health and chronic pain management: current status and developments. Pain. 2010 Oct;151(1):18-21. doi: 10.1016/j.pain.2010.07.014. Epub 2010 Jul 31. Review. — View Citation
Macea DD, Gajos K, Daglia Calil YA, Fregni F. The efficacy of Web-based cognitive behavioral interventions for chronic pain: a systematic review and meta-analysis. J Pain. 2010 Oct;11(10):917-29. doi: 10.1016/j.jpain.2010.06.005. Epub 2010 Jul 22. Review. — View Citation
Mariano TY, Wan L, Edwards RR, Jamison RN. Online teletherapy for chronic pain: A systematic review. J Telemed Telecare. 2021 May;27(4):195-208. doi: 10.1177/1357633X19871746. Epub 2019 Sep 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of eligible participants identified per programme | Prior to each programme the number of eligible participants will be recorded by the primary researcher | Baseline | |
Primary | Number of eligible participants recruited per programme | Prior to each programme the number of eligible participants who are recruited will be recorded by the primary researcher | Baseline | |
Primary | Reasons for non-participation | This measure will be recorded by the primary researcher when screening participants | Baseline | |
Primary | Number of participants who complete the study | The number of participants that complete >50% of the online classes programme | immediately post intervention (8 weeks from baseline) | |
Primary | Adherence to completion of baseline patient reported outcome measures | Numbers of participants completing > 90% of baseline patient reported outcome measures | Baseline | |
Primary | Adherence to completion of immediate follow-up patient reported outcome measures | Numbers of participants completing > 90% of follow-up patient reported outcome measures | Immediately post intervention (8 weeks from baseline) | |
Primary | Adherence to completion of long term follow-up patient reported outcome measures | Numbers of participants completing > 90% of follow-up patient reported outcome measures | 3 months post intervention (20 weeks from baseline) | |
Primary | Interaction with online self-management guide | The study website analytics will measure the number of views that each element of the online guide receives (Group B) | Immediately post intervention (8 weeks from baseline) | |
Primary | Treatment Acceptability (Satisfaction assessed by Client Satisfaction Questionnaire-8) | Patient satisfaction with treatment will be measured with an adapted version of the Client Satisfaction Questionnaire-8. Responses are scored from 1-4, and the possible total scores range from 8 to 32. Higher scores indicate greater satisfaction. | Immediately post intervention (8 weeks from baseline) | |
Primary | Interface usability | Measures of website usability will be investigated with an adapted System Usability Scale (SUS) Scores range from 10-50. Higher scores indicated greater ease of usability. | immediately post intervention (8 weeks from baseline) | |
Secondary | Change in pain self-efficacy measured with the Pain Self-Efficacy Questionnaire | The Pain Self-Efficacy Questionnaire is a ten item questionnaire which assesses an individual's confidence in their ability to perform a variety of activities or tasks despite pain. Scores can range from 0 - 60. Higher scores represent lower confidence to function with pain. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Change in symptoms of anxiety measured with the Generalized Anxiety Disorder Assessment | The Generalized Anxiety Disorder 7 assesses symptoms of anxiety experienced during the last two weeks. The total score for the seven items ranges from 0 to 21. Higher scores represent higher levels of anxiety. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Changes in symptoms of depression measured with the Patient Health Questionnaire 9 | Symptoms of depression will be assessed using the Patient Health Questionnaire 9, which is a nine-item questionnaire generating scores ranging from 0-27. Higher scores indicate increased severity of depression. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Changes in pain severity and pain interference measured with the Brief Pain Inventory-Composite pain score | Pain severity will be measured using the pain severity subscale of the Brief Pain Inventory. Pain interference will be measured using the interference subscale of the Brief Pain Inventory, which measures the extent to which pain interferes with functions such as general activity, walking ability, normal work, mood, relationships with people, enjoyment of life and sleep. For each scale, the total score is the average of all items (range, 0-10), where a higher score indicates greater severity and more interference. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Changes in the impact of pain on individuals life participation measured with the Pain Disability Index | The Pain Disability Index measure asks patients to rate how much pain interferes in seven areas of life activity: family/home, recreation, social, occupation, sexual, self-care and life-support. Total score ranges from 0-70. The higher the score the greater the person's disability due to pain. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Changes in fear avoidance of physical activity measured with the Fear Avoidance Belief Questionnaire. | The Fear Avoidance Belief Questionnaire measures patients' fear of pain and consequent avoidance of physical activity because of their fear. The questionnaire consists of 16 items in which a patient rates their agreement with each statement on a 7-point Likert scale. The scores range from 0-96; higher scores indicates increased fear avoidance behaviours. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Change in pain catastrophising measured with the Pain Catastrophising Scale. | The Pain Catastrophising Scale is a 13-item instrument designed to assess catastrophic thinking in relation to pain. It yields a total score and three subscale scores assessing rumination, magnification and helplessness. Scores range from 0-52. Higher scores are associated with higher amounts of pain catastrophising. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Change in quality of life measured with the Short Form-36 Health Survey | The Short Form-36 Health Survey comprises of 36 questions which cover eight domains of general health. Scores range from 0-100. The lower the score the more disability. | immediately post intervention (8 weeks from baseline) and 12 week follow up (20 weeks from baseline) | |
Secondary | Patient Global Impression of Change Scale | The Patient Global Impression of Change Scale scale measures a patient's rating of overall improvement or lack thereof due to the intervention. It is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." | immediately post intervention (8 weeks from baseline) | |
Secondary | Changes in step count (Fitbit) | Average weekly step count will be measured using a Fitbit Charge 4 activity monitor worn by participants for the eight weeks of the intervention. | immediately post intervention (8 weeks from baseline) | |
Secondary | Changes in distance travelled (Fitbit) | Average weekly distance travelled will be measured using a Fitbit Charge 4 activity monitor worn by participants for the eight weeks of the intervention. | immediately post intervention (8 weeks from baseline) | |
Secondary | Changes in active minutes (Fitbit) | Average active minutes will be measured using a Fitbit Charge 4 activity monitor worn by participants for the eight weeks of the intervention. | immediately post intervention (8 weeks from baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|